← All trials
NCT05507671
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Aug 19, 2022
- Last posted
- Aug 19, 2022
- Enrollment
- 556
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- Federal University of Juiz de ForaCollaborator
- Oswaldo Cruz FoundationOverall official - principal investigator
- Oswaldo Cruz FoundationStudy chair
- University of CampinasStudy chair
- University of Sao PauloCollaborator
- University of Sao PauloStudy chair
- University of CampinasOfficial
- Oswaldo Cruz FoundationOfficial
- University of Sao PauloOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.